As the age of antibiotics falters under the weight of resistance, a team at Hebrew University of Jerusalem has uncovered a molecular secret hidden for seventy-five years inside one of science's most studied viruses. The discovery of PreS — an RNA switch that enables bacteriophages to commandeer and destroy bacterial cells from within — offers a new foothold in humanity's oldest struggle against infection. With over a million lives lost annually to resistant bacteria, this quiet breakthrough in molecular listening may help restore what modern medicine has slowly been losing.
The Times of Israel
· Dec 19, 2025
· health
· 3 min de leitura
High
Apuração: Verificado
Hebrew University scientists discover RNA 'switch' that could unlock phage therapy against superbugs
Antibiotic-resistant bacteria directly caused 1.27 million deaths globally in 2019, with approximately 5,000 Israelis dying annually from resistant infections.
◉
Education
1014 artigos relacionados
Brown professor exposes 40-student AI cheating scandal, criticizes uni…
Fox News · 100% correspondência
Low CLAT Score? Here's Your Roadmap to Law School Through Alternate Ex…
The Indian Express · 99% correspondência
Universities face pressure over campus antisemitism as royal commissio…
The Guardian · 90% correspondência
UC Faculty Push to Reinstate SAT/ACT Math Requirements After Student P…
Fox News · 90% correspondência
UTA researchers develop noninvasive test to pinpoint epilepsy networks…
News-Medical.net · 90% correspondência
Cobertura Relacionada
The Guardian · Jul 21
Academics urge Burnham to adopt £10bn wealth tax on UK's super-rich
Academics propose a 2% wealth tax on UK households exceeding £100m, potentially raising £10bn yearly while affecting few…
Inquirer.net · Jul 21 Cotabato girl dies from rabies; health workers trace funeral attendees for vaccinationA Grade One student in Cotabato died from rabies after possible exposure through animal contact. Health authorities are …
The Energy Mix · Jul 21 Flow Batteries Scale Up: China's Breakthrough Sparks European CompetitionChina deployed the world's first large-scale flow battery project in January, with European developers building larger s…
CBS News · Jul 21 U.S. gas prices surge back to $4 a gallon amid Iran tensionsU.S. average gas prices have climbed back to $4 per gallon, rising 13 cents weekly as geopolitical tensions with Iran es…
Viés e Enquadramento
⚖
Article presents scientific discovery with institutional pride framing; minimal bias detected in reporting of research findings and global health context.
Bias Direction
center
Confidence
MED
Institutional achievement narrative combined with global health crisis framing to establish urgency and relevance of the research
unlock
war against superbugs
defy antibiotics
global health threat
Skeptical scientific voices or limitations of phage therapy
Timeline and realistic expectations for clinical applications
Perspectives from pharmaceutical industry or competing research approaches
Patient or public health official commentary on phage therapy potential
Impacto Geopolítico
🌎
Hebrew University's discovery of PreS RNA molecule advances phage therapy against antibiotic-resistant bacteria, potentially reshaping global antimicrobial treatment strategies and reducing dependence on conventional antibiotics.
Escalation Risk
low
Confidence
HIGH
Global
Israel
United States
European Union
Developing nations with high antimicrobial resistance burden
Scientific leadership in biotechnology shifts toward institutions pioneering alternative therapies; Israel-US research collaboration strengthens; nations with advanced biotech sectors gain competitive advantage in addressing global health crises; potential reduction in pharmaceutical industry's antibiotic monopoly.
Similar to the penicillin discovery (1928) that revolutionized medicine and shifted global health paradigms; represents a return to phage therapy research abandoned after antibiotics' rise, now necessitated by resistance crisis.
Lente Econômica
📈
Hebrew University discovery of PreS RNA molecule enables bacteriophage therapy against antibiotic-resistant bacteria, potentially creating new biotech market opportunities as antimicrobial resistance costs global healthcare systems billions annually.
Market Signal
bullish
Confidence
MED
Biotechnology and pharmaceutical manufacturing
Healthcare and hospital services
Medical research and development
Diagnostic testing services
Agricultural antibiotics market (potential substitution)
Consumers facing antibiotic-resistant infections could gain access to alternative treatments, potentially reducing hospitalization costs and mortality rates. Long-term healthcare expenses may decrease as phage therapy becomes commercialized, though initial adoption costs may be high.
Governments may accelerate regulatory pathways for phage therapy approval (FDA, EMA). Increased R&D funding for alternative antimicrobial solutions likely. Potential restrictions on agricultural antibiotic use to preserve effectiveness. International coordination on antimicrobial stewardship programs expected to intensify.